Administrative Core-Interdisciplinary Ctr for Male Contraceptive Res & Drug Dev

分配给U 54男性避孕研究跨学科中心的空间摘要 药物发现： 新的生物医学研究中心（BRC）将容纳所有U 54研究项目的主要研究者 和两个支援核心单位堪萨斯大学医学中心将完成一个新的 5200万美元的研究大楼，包含179，582净可分配平方英尺（NASF）。占领这栋楼 计划于2006年10月开始，2006年12月完成，将包括实验室、办公室 所有U 54研究项目主要研究者以及行政管理人员的研究支持空间 和U 54中心的成像核心。这些都将位于33，294平方英尺的三楼 （见下页图1）。这层楼也将被跨学科中心占用， 男性避孕研究和药物开发以及生殖科学中心，因此 代表了一个高度互动，协作和支持性的环境进行研究，男性 避孕的发展。布拉迪斯拉发区域中心的各个实验室将配备齐全;没有要求 设备，因为大学已经为所有与U 54相关的实验室提供了新设备。在适当的情况下， 研究人员将自己实验室的设备集中到核心，以减少重复 和成本。然而，核心区的大部分设备（实验室和行政设备）是由 医学院院长办公室和匹配以前的NIH赠款。此外，2700万美元 霍尔家庭基金会赠送给堪萨斯大学医学中心的礼物，用于购买 所有调查员和核心人员的新设备和替换设备都将迁入布拉迪斯拉发区域中心。 药物，发现，设计和合成核心（DDS核心）位于密歇根大学的设施中。 堪萨斯-劳伦斯大学和明尼苏达大学。这些都是目前正在建设的核心设施， 在我们的多校区NICHD合同中使用“非激素非类固醇男性的合成和测试” 避孕药。“堪萨斯-劳伦斯大学的设施位置距离 堪萨斯大学医学中心。在目前和以前的男性避孕药具开发合同期间， 两地的距离并不妨碍研究工作的顺利进行。 根据OSHA法规，药物、发现、设计和合成核心向研究人员提交的化合物 在堪萨斯大学医学中心，必须由商业承运人运输（如FEDEX隔夜）。 这一程序将继续在U 54中心，以及在明尼苏达大学的设施之间 以及中心的其他校区确保良好沟通的其他行政安排 核心组件和中心其余部分之间的联系包括：1）安全的基于Web的数据存储库 用于化学、物理和生物数据。2)塔什博士，格奥尔格博士和美泉宫博士将在 至少每六个月（额外的差旅费将由其他资金来源支付），以确保 核心需求正在得到顺利满足。3)最后，所有涉及研究中心研究者的研讨会和会议将 在两个校区通过网络视频会议提供。 药物开发核心（DD核心）位于大学设施的行政空间， 在堪萨斯医学中心和堪萨斯-劳伦斯大学。这个核心可能是独一无二的， 学术中心。核心由Scott Weir（Pharm.D，Ph.D.）领导。Weir博士的专业领域包括 在临床药理学和开发创新的方法在铅优化和早期药物开发。 博士伟尔在广泛的治疗领域开发了药物产品。DD核心设施位于 KUMC位于BRC街对面，研究项目实验室和行政和成像 核心是定位。

Summary of space allocated for the U54 Interdisciplinary Center for Male Contraceptive Research and Drug Discovery: New Biomedical Research Center (BRC) will house all U54 Research Project Principal Investigators and two support Core Units. The University of Kansas Medical Center will complete construction of a new $52 million research building containing 179,582 Net Assignable Square Feet (NASF). Occupancy of this building is schedule to begin in October, 2006 and be completed by December, 2006 and will include laboratory, office, and research support space for all of the U54 Research Project Principal Investigators as well as the Administrative and Imaging Cores of the U54 Center. These will all be located on the 33,294 square foot 3rd floor of the BRC (see Figure 1, next page). This floor will also be occupied by both the Interdisciplinary Center for Male Contraceptive Research and Drug Development and the Center for Reproductive Sciences, and thus represents a highly interactive, collaborative, and supportive environment for conducting the research on male contraceptive development. The individual labs in the BRC will be well equipped; there are no requests for equipment since the university has provided new equipment for all labs associated with this U54. Where appropriate, investigators have centralized equipment from their own labs into the core in order to reduce duplication and costs. However, most of the equipment in the cores (laboratories and administrative) was provided by the Dean's office of the School of Medicine and by matching of previous NIH grants. In addition, a $27 million gift from the Hall Family Foundation to the University of Kansas Medical Center provided for the purchase of new and replacement equipment for all of the investigators and cores moving into the BRC. The Drug, Discovery, Design & Synthesis Core (DDS Core) is housed in facilities at the University of Kansas-Lawrence and at the University of Minnesota. These are the same core facilities that are currently being utilized in our multi-campus NICHD contract "Synthesis and Testing of Non-hormonal Non-Steroidal Male Contraceptive Agents." The location of the facility at University of Kansas-Lawrence is about 30 miles from the University of Kansas Medical Center. During the current and previous contract on male contraceptive development, this distance provides no barrier to the smooth conduct of the research between the two campuses. Due to OSHA regulations, compounds submitted by the Drug, Discovery, Design & Synthesis core to investigators at University of Kansas Medical Center must be transported by commercial carriers (such as FEDEX overnight). This procedure will continue in the U54 center, as well as between the facilities at the University of Minnesota and the other campuses in the Center. Other administrative arrangements to ensure good communications between the core components and the rest of the center include: 1) A secure web-based data repository for chemical, physical, and biological data. 2) Drs. Tash, Georg, and Schonbrunn will be meet face-to-face at least every six months (additional travel costs will be covered by alternate funding sources) to make sure the core needs are being met smoothly. 3) Finally, all seminars and meetings involving center investigators will be available by web video conference at both campuses. The Drug Development Core (DD Core) is located in administrative space in facilities at both the University of Kansas Medical Center and at the University of Kansas-Lawrence. This core is probably unique in an academic center. The core is headed by Scott Weir, Pharm.D, Ph.D.. Dr. Weir's specific areas of expertise are in clinical pharmacology and developing innovative approaches in lead optimization and early drug development. Dr. Weir has developed drug products across a wide range of therapeutic areas. The DD Core facility at KUMC is located across the street from the BRC, where the research project labs and Administrative and Imaging cores are located.